Azeria Banks £32m For New Breast Cancer Approach
UK Firm Added To Syncona Portfolio
Azeria has closed a significant series B round to fund development of novel breast cancer drugs targeting pioneer factors.
Azeria has closed a significant series B round to fund development of novel breast cancer drugs targeting pioneer factors.